Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells

References

• Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22:371-83; PMID:15780993; http://dx.doi.org/10.1016/j.immuni.2005.02.003
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sorlie T, Warnberg F, Haakensen VD, Helland A et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012; 109:2802-7; PMID:21908711; http://dx.doi.org/10.1073/pnas.1108781108
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A et al. How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol 2014; 5:174; PMID:24782871; http://dx.doi.org/10.3389/fimmu.2014.00174
   PubMed Web of Science ®Google Scholar
• Corthay A. Does the Immune System Naturally Protect Against Cancer? Front Immunol 2014; 5:197; PMID:24860567; http://dx.doi.org/10.3389/fimmu.2014.00197
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Pace JL, Russell SW, Altman A, Katz DH. Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. Journal of immunology 1983; 131:826-32; PMID:NOT_FOUND
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-5
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Bogen B, Corthay A. A model for cancer-suppressive inflammation. Oncoimmunology 2012; 1:1146-55; PMID:23170261; http://dx.doi.org/10.4161/onci.21542
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van Hall T, van der Burg SH. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011; 187:1157-65; PMID:21709158; http://dx.doi.org/10.4049/jimmunol.1100889
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx.doi.org/10.1016/j.ccr.2009.06.018
   PubMed Web of Science ®Google Scholar
• Bogen B, Gleditsch L, Weiss S, Dembic Z. Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur J Immunol 1992; 22:703-9; PMID:1547816; http://dx.doi.org/10.1002/eji.1830220313
   PubMed Web of Science ®Google Scholar
• Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 1994; 91:5700-4; PMID:7911244; http://dx.doi.org/10.1073/pnas.91.12.5700
   PubMed Web of Science ®Google Scholar
• Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 1995; 25:3079-86; PMID:7489746; http://dx.doi.org/10.1002/eji.1830251114
   PubMed Web of Science ®Google Scholar
• Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer research 2009; 69:5901-7; PMID:19567679; http://dx.doi.org/10.1158/0008-5472.CAN-08-4816
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, Corthay A. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011; 2:240; PMID:21407206; http://dx.doi.org/10.1038/ncomms1239
   PubMed Web of Science ®Google Scholar
• Lorvik KB, Bogen B, Corthay A. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood 2012; 119:2176-7; PMID:22383793; http://dx.doi.org/10.1182/blood-2011-10-388892
   PubMed Web of Science ®Google Scholar
• Lorvik KB, Haabeth OAW, Clancy T, Bogen B, Corthay A. Molecular profiling of tumor-specific Th1 cells activated in vivo. OncoImmunology 2013; 2:e24383; PMID:23762808; http://dx.doi.org/10.4161/onci.24383
   PubMedGoogle Scholar
• Peri G, Polentarutti N, Sessa C, Mangioni C, Mantovani A. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin. Int J Cancer 1981; 28:143-52; PMID:6172388; http://dx.doi.org/10.1002/ijc.2910280206
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11323675; http://dx.doi.org/10.1038/35074122
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95:7556-61; PMID:9636188; http://dx.doi.org/10.1073/pnas.95.13.7556
   PubMed Web of Science ®Google Scholar
• Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72:3666-70; PMID:1103152; http://dx.doi.org/10.1073/pnas.72.9.3666
   PubMed Web of Science ®Google Scholar
• Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189:1343-54; PMID:10209050; http://dx.doi.org/10.1084/jem.189.8.1343
   PubMed Web of Science ®Google Scholar
• Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192:1373-80; PMID:11067885; http://dx.doi.org/10.1084/jem.192.9.1373
   PubMed Web of Science ®Google Scholar
• Halaas O, Vik R, Ashkenazi A, Espevik T. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol 2000; 51:244-50; PMID:10736093; http://dx.doi.org/10.1046/j.1365-3083.2000.00671.x
   PubMed Web of Science ®Google Scholar
• Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4:353-60; PMID:1420996; http://dx.doi.org/10.1016/1043-4666(92)90078-6
   PubMed Web of Science ®Google Scholar
• Nakamura S, Nakata K, Kashimoto S, Yoshida H, Yamada M. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors. Jpn J Cancer Res 1986; 77:767-73; PMID:3093425
   PubMedGoogle Scholar
• North RJ, Neubauer RH, Huang JJ, Newton RC, Loveless SE. Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med 1988; 168:2031-43; PMID:3143799; http://dx.doi.org/10.1084/jem.168.6.2031
   PubMed Web of Science ®Google Scholar
• Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M, White RM, Zoller M, Barak V, Segal S et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res 1999; 59:1029-35; PMID:10070959
   PubMed Web of Science ®Google Scholar
• Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, Bjorkdahl O, Segal S, Dinarello CA et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 2003; 171:6448-56; PMID:14662844; http://dx.doi.org/10.4049/jimmunol.171.12.6448
   PubMed Web of Science ®Google Scholar
• Von Stebut E, Ehrchen JM, Belkaid Y, Kostka SL, Molle K, Knop J, Sunderkotter C, Udey MC. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med 2003; 198:191-9; PMID:12860932; http://dx.doi.org/10.1084/jem.20030159
   PubMed Web of Science ®Google Scholar
• Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, Dinarello CA, Paul WE. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A 2009; 106:7119-24; PMID:19359475; http://dx.doi.org/10.1073/pnas.0902745106
   PubMed Web of Science ®Google Scholar
• Koide SL, Inaba K, Steinman RM. Interleukin 1 enhances T-dependent immune responses by amplifying the function of dendritic cells. J Exp Med 1987; 165:515-30; PMID:2950198; http://dx.doi.org/10.1084/jem.165.2.515
   PubMed Web of Science ®Google Scholar
• Ben-Sasson SZ, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank M, Caucheteux S, Ratner-Hurevich M, Berzofsky JA, Nir-Paz R et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med 2013; 210:491-502; PMID:23460726; http://dx.doi.org/10.1084/jem.20122006
   PubMed Web of Science ®Google Scholar
• Schultz RM, Kleinschmidt WJ. Functional identity between murine gamma interferon and macrophage activating factor. Nature 1983; 305:239-40; PMID:6412144; http://dx.doi.org/10.1038/305239a0
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8; PMID:9851930; http://dx.doi.org/10.1126/science.282.5396.2085
   PubMed Web of Science ®Google Scholar
• Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 1998; 95:588-93; PMID:9435236; http://dx.doi.org/10.1073/pnas.95.2.588
   PubMed Web of Science ®Google Scholar
• Hori K, Mihich E, Ehrke MJ. Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages. Cancer Res 1989; 49:2606-14; PMID:2496917
   PubMed Web of Science ®Google Scholar
• Niinobu T, Fukuo K, Yasuda O, Tsubakimoto M, Mogi M, Nishimaki H, Morimoto S, Ogihara T. Negative feedback regulation of activated macrophages via Fas-mediated apoptosis. American journal of physiology Cell physiology 2000; 279:C504-9; PMID:10913017
   PubMedGoogle Scholar
• Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 2012; 30:3396-401; PMID:22915661; http://dx.doi.org/10.1200/JCO.2011.40.0655
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Turksma AW, Powell Jr DJ, Hooijberg E, de Gruijl TD. IL-21 in cancer immunotherapy: At the right place at the right time. Oncoimmunology 2013; 2:e24522; PMID:23894713; http://dx.doi.org/10.4161/onci.24522
   PubMedGoogle Scholar
• Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Jr., Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P et al. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer 2014; 2:2; PMID:24829759; http://dx.doi.org/10.1186/2051-1426-2-2
   PubMedGoogle Scholar
• Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 2010; 16:4188-97; PMID:20587591; http://dx.doi.org/10.1158/1078-0432.CCR-10-0173
   PubMed Web of Science ®Google Scholar
• Zorzoli A, Di Carlo E, Cocco C, Ognio E, Ribatti D, Ferretti E, Dufour C, Locatelli F, Montagna D, Airoldi I. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg−/− mice. Clin Cancer Res 2012; 18:1630-40; PMID:22383738; http://dx.doi.org/10.1158/1078-0432.CCR-11-2432
   PubMed Web of Science ®Google Scholar
• Swarbrick A, Junankar SR, Batten M. Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy? Oncoimmunology 2013; 2:e25409; PMID:24083081; http://dx.doi.org/10.4161/onci.25409
   PubMedGoogle Scholar
• Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol 2009; 30:227-33; PMID:19359217; http://dx.doi.org/10.1016/j.it.2009.03.003
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 2014; 74:1789-800; PMID:24448242; http://dx.doi.org/10.1158/0008-5472.CAN-13-2729
   PubMed Web of Science ®Google Scholar
• Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, Lu J, Qin W, Qi Y, Xie F et al. Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells. J Immunol 2015; 194:438-45; PMID:25429071; http://dx.doi.org/10.4049/jimmunol.1401344
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45; PMID:11229684; http://dx.doi.org/10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http://dx.doi.org/10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48:526-35; PMID:11247898; http://dx.doi.org/10.1136/gut.48.4.526
   PubMed Web of Science ®Google Scholar
• Polk DB, Peek RM, Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10:403-14; PMID:20495574; http://dx.doi.org/10.1038/nrc2857
   PubMed Web of Science ®Google Scholar
• Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, Askling J. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48:963-70; PMID:12687538; http://dx.doi.org/10.1002/art.10939
   PubMed Web of Science ®Google Scholar
• Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995; 85:765-71; PMID:7530507
   PubMed Web of Science ®Google Scholar
• Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997; 127:186-94; PMID:9245223; http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00002
   PubMed Web of Science ®Google Scholar
• Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito MJ, Oramas J. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80-6; PMID:10080883; http://dx.doi.org/10.1006/cyto.1998.0398
   PubMed Web of Science ®Google Scholar
• Bani MR, Garofalo A, Scanziani E, Giavazzi R. Effect of interleukin-1-beta on metastasis formation in different tumor systems. J Natl Cancer Inst 1991; 83:119-23; PMID:1988686; http://dx.doi.org/10.1093/jnci/83.2.119
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003; 100:2645-50; PMID:12598651; http://dx.doi.org/10.1073/pnas.0437939100
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379(9826):1591-601; PMID:22440947
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379(9826):1602-12; PMID:22440946
   PubMed Web of Science ®Google Scholar
• Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13(5):518-27; PMID:22440112
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028
   PubMed Web of Science ®Google Scholar
• Bogen B, Lauritzsen GF, Weiss S. A stimulatory monoclonal antibody detecting T cell receptor diversity among idiotype-specific, major histocompatibility complex-restricted T cell clones. Eur J Immunol 1990; 20:2359-62; PMID:1700755; http://dx.doi.org/10.1002/eji.1830201030
   PubMed Web of Science ®Google Scholar
• Inoue A, Koh CS, Yahikozawa H, Yanagisawa N, Yagita H, Ishihara Y, Kim BS. The level of tumor necrosis factor-alpha producing cells in the spinal cord correlates with the degree of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Int Immunol 1996; 8:1001-8; PMID:8757945; http://dx.doi.org/10.1093/intimm/8.7.1001
   PubMed Web of Science ®Google Scholar
• Wang HH, McIntosh AR, Hasinoff BB, Rector ES, Ahmed N, Nance DM, Orr FW. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res 2000; 60:5862-9; PMID:11059784
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7:94-100; PMID:11135622; http://dx.doi.org/10.1038/83416
   PubMed Web of Science ®Google Scholar
• Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K et al. Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med 2011; 2:103-8; PMID:22977477
   PubMed Web of Science ®Google Scholar